Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2024) 99 EP437 | DOI: 10.1530/endoabs.99.EP437

1Clinic for Endocrinology, Diabetes and Metabolic Diseases, University Clinical Centre of Serbia, Department for Endocrine Tumors and Hereditary Cancer Syndromes, Belgrade, Serbia; 2University Medical Centre Bezanijska Kosa, Belgrade, Serbia; 3Institute of Physiology, Faculty of Medicine, Belgrade, Serbia; 4IBISS, University of Belgrade, Belgrade, Serbia


Introduction: 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) is a dimeric enzyme that catalyzes the reduction of cortisone to cortisol within the endoplasmic reticulum. Loss of this activity results in a disorder termed cortisone reductase deficiency type 1 (CRD). Only mutations in H6PD gene, which encodes an enzyme supplying cofactor for the reaction, have been identified as the cause of disease. Biochemical features of CRD are increased cortisol clearance and ACTH-mediated androgen excess. There are close phenotypic similarities between CRD and polycystic ovary syndrome (PCOS): hirsutism, oligo-amenorrhea, central fat distribution, infertility. We present the case of a 21-year old woman with mutations in H6PD gene who presented with secondary amenorrhea, hirsutism and obesity.

Case: After menarche at the age of 12, there were no spontaneous periods. A pediatric endocrinologist diagnosed PCOS (Rotterdam phenotype A). Menstrual cycles (MC) were established with a combined oral contraceptive pill with antiandrogen properties. The breaks in taking the medicine was followed by absence of MC. The patient’s dominant complaints are hirsutism (mFG score - 10), obesity (BMI 33 kg/m2) and secondary amenorrhea.

Results: Investigations showed elevated basal values of androgens (testosterone 6.8 and 8.0 nmol/l [1.2-3.8 nmol/l], androstenedione 6.2 and 6.0 ng/ml [0.24-3.44 ng/ml] and 17-OH progesterone 7.2 and 7.1 nmol/l [0.4-5.0nml/l]), FAI 29.8, AMH 9.45 ng/ml; DHEAS, serum cortisol, IGF-1, prolactin and thyroid function were normal. The results obtained in 2h-OGTT indicate insulin resistance (HOMA-IR 10.5). In low-dose dexamethasone tests, including prolonged DEX I, androgen suppression was absent. Androgen suppression was occurred after administration of GnRH agonist (Diphereline 3.75 mg). Congenital adrenal hyperplasia (CAH) was biochemically excluded by the Synachten test (maximal 17-OHP 7.0 nmol/l and cortisol 685.4 nmol/l). Selective ovarian and adrenal venous sampling were inconclusive indicating abnormal androgen production from the left adrenal gland and right ovary. Genetic analyzes confirmed mutations in H6PD gene: c.455A>G (p. Tyr152Cys) and c.1123G>A (p. Glu375Lys). The result of cortisol clearance is pending. The enlarged ovaries (diameter 5 cm, volume 28 ml) with polycystic morphology were confirmed by ultrasound. Adrenal glands are described as normal (MRI).

Conclusion: The genetic analysis on H6PD gene should be done if there are inexplicably high levels of androgens in a woman with PCO-like phenotype. Peculiar functional testing is needed including specific genetic testing for rare adrenal enzymatic deficiencies.

Volume 99

26th European Congress of Endocrinology

Stockholm, Sweden
11 May 2024 - 14 May 2024

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

Pigarova Ekaterina (<1 min ago)
Yassmine Elloumi (<1 min ago)
Panagaki Maria (<1 min ago)
Sara (<1 min ago)
Marianne (<1 min ago)